A fluorescent styrylquinoline with combined therapeutic and diagnostic activities against alzheimer’s and prion diseases

Simple item page
dc.contributor.authorStaderini, Matteo
dc.contributor.authorAulić, Suzana
dc.contributor.authorBartolini, Manuela
dc.contributor.authorTran, Hoang Ngoc Ai
dc.contributor.authorGonzález-Ruiz, Víctor
dc.contributor.authorPérez, Daniel I.
dc.contributor.authorMartínez Gil, Ana
dc.contributor.authorAndrisano, Vincenza
dc.contributor.authorLegname, Giuseppe
dc.contributor.authorMenéndez Ramos, José Carlos
dc.contributor.authorBolognesi, Maria Laura
dc.contributor.authorCabezas Baudot, Nieves
dc.contributor.authorMartín Carmona, María Antonia
dc.date.accessioned2024-02-07T09:28:36Z
dc.date.available2024-02-07T09:28:36Z
dc.date.issued2013-01-03
dc.description.abstract(E)-6-Methyl-4′-amino-2-styrylquinoline (3) is a small molecule with the proper features to potentially diagnose, deliver therapy and monitor response to therapy in protein misfolding diseases. These features include compound fluorescent emission in the NIR region and its ability to interact with both Aβ and prion fibrils, staining them with high selectivity. Styrylquinoline 3 also inhibits Aβ self-aggregation in vitro and prion replication in the submicromolar range in a cellular context. Furthermore, it is not toxic and is able to cross the blood brain barrier in vitro (PAMPA test).
dc.description.departmentDepto. de Química en Ciencias Farmacéuticas
dc.description.facultyFac. de Farmacia
dc.description.refereedTRUE
dc.description.sponsorshipMinisterio de Ciencia, Innovación y Universidades (España)
dc.description.sponsorshipUniversidad Complutense de Madrid
dc.description.sponsorshipMinistero dell ́ ’Istruzione, dell’Università e della Ricerca (Italia)
dc.description.sponsorshipConsejo Superior de Investigaciones Científicas
dc.description.statuspub
dc.identifier.citationStaderini M, Aulić S, Bartolini M, Tran HNA, González-Ruiz V, Pérez DI, et al. A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer’s and Prion Diseases. ACS Med Chem Lett 2013;4:225–9. https://doi.org/10.1021/ml300360
dc.identifier.doi10.1021/ml3003605
dc.identifier.issn1948-5875
dc.identifier.officialurlhttps://doi.org/10.1021/ml3003605
dc.identifier.urihttps://hdl.handle.net/20.500.14352/99813
dc.issue.number2
dc.journal.titleACS Medicinal Chemistry Letters
dc.language.isoeng
dc.page.final229
dc.page.initial225
dc.publisherACS publications
dc.relation.projectIDinfo:eu-repo/grantAgreement/MICINN/CTQ2009-12320-BQU
dc.relation.projectIDinfo:eu-repo/grantAgreement/MICINN/SAF2009-13015-C02-01
dc.relation.projectIDinfo:eu-repo/grantAgreement/GR35/10-A-920234
dc.relation.projectIDinfo:eu-repo/grantAgreement/PRIN2008
dc.relation.projectIDinfo:eu-repo/grantAgreement/PRIN2009
dc.relation.projectIDinfo:eu-repo/grantAgreement/PRIN2010
dc.rights.accessRightsrestricted access
dc.subject.keywordAggregation
dc.subject.keywordprotein misfolding diseases
dc.subject.keywordamyloid
dc.subject.keywordfibrillation inhibitors
dc.subject.ucmQuímica analítica (Farmacia)
dc.subject.unesco2301 Química Analítica
dc.titleA fluorescent styrylquinoline with combined therapeutic and diagnostic activities against alzheimer’s and prion diseases
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number4
dspace.entity.typePublication
relation.isAuthorOfPublication4c8ca147-677d-4846-97b7-d4419662ff60
relation.isAuthorOfPublication65dee307-737c-4ac4-8d8a-8db43e2110cf
relation.isAuthorOfPublication711c3146-caca-4061-9626-60a946a50f20
relation.isAuthorOfPublication.latestForDiscovery65dee307-737c-4ac4-8d8a-8db43e2110cf
Download
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Staderini-A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer’s and Prion Diseases-2013-ACS Medicinal Chemistry Letters.pdf
Size:
1.45 MB
Format:
Adobe Portable Document Format
Download
Collections
Artículos